Diagnostic and Interventional Cardiology (DAIC) published an article, written by electrophysiologist Dr. Michael Mirro, sharing his perspective on the results of the Vest Prevention of Early Sudden Death Trial (VEST). Dr. Mirro is the chief academic research officer at Parkview Health in Ft. Wayne, Indiana and is the director of the Mirro Center for Research and Innovation at Parkview, where he specializes in clinical research in cardiac electrophysiology and health informatics.
The VEST Trial is a multi-center, randomized controlled trial of LifeVest use in patients who have recently suffered a heart attack (medically known as “post-myocardial infarction” or “post-MI”) and have a reduced heart function (medically known as a low “ejection fraction” or “EF” of 35 percent or less). 2,302 patients were randomized to receive LifeVest plus guideline-directed medical therapy (GDMT) or GDMT alone for 90 days following a heart attack. In the article, Dr. Mirro provides an in-depth review of the trial’s key findings.
Dr. Mirro has served as a member of the Board of Trustees of the American College of Cardiology (ACC) and has served as the Co-Chair of the ACC Advocacy Committee and Chair of the ACC HIT Committee. He is also a member of the Certification Commission for Health Information Technology, serving as Co-chair of the Cardiovascular Work Group and the Advanced Quality Workgroup.